Borja Jesús Hernández García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Borja Jesús Hernández García has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Javier Egea
Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Instituto de Investigación Sanitaria-Princesa IIS-IP, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
4 shared publications - Víctor Farré-Alins
Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Instituto de Investigación Sanitaria-Princesa IIS-IP, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
4 shared publications - Ana Belen Lopez-Rodriguez
Department of Neurology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Madrid, Spain
3 shared publications - Celine Decouty-Pérez
Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Instituto de Investigación Sanitaria-Princesa IIS-IP, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
3 shared publications - Javier Giner
Servicio de Neurocirugía, Hospital Universitario La Paz, Madrid, España
3 shared publications Alberto Isla
Servicio de Neurocirugía, Hospital Universitario La Paz, Madrid, España
2 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 571
Uncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury
Traumatic brain injury (TBI) is a highly heterogeneous disease and achieving an accurate diagnosis remains a significant challenge. Biomarkers play a crucial role in minimizing the reliance on invasive techniques like computed tomography, which also have significant economic costs. Human samples were obtained from prospective cohort studies. Mice were subjected to an experimental model of traumatic brain injury. Biomarker levels, gene expression, and blood–brain barrier integrity were analyzed using ELISA, qRT-PCR, and Evans Blue assay; data were statistically evaluated using parametric or non-parametric tests as appropriate. This study focuses on evaluating the role of matricellular protein thrombospondin-1 (TSP-1) and the tight junction proteins occludin and ZO-1 as potential biomarkers of TBI. We showed that lower serum TSP-1 levels correlated with poor patient outcomes at 6 months compared to those patients with a good outcome. Additionally, the disruption of the blood–brain barrier (BBB) and subsequent release of tight junction proteins allowed us to identify occludin as a potential biomarker for prognosis in a cohort of TBI patients and as a diagnosis biomarker in a subgroup of patients with mild TBI, but its discriminative power as a diagnosis biomarker appears modest, as reflected by an AUC of 0.693. On the other hand, ZO-1 exhibited increased levels but limited diagnostic utility. These findings highlight the critical role of TSP-1 in maintaining BBB integrity and regulating the inflammatory response after a TBI, supported by the worsened condition observed in TSP-1-deficient animals. These results demonstrate the potential of TSP-1 and occludin as valuable biomarkers for secondary injury and disease progression in patients with mild to moderate/severe TBI.
- 6 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 571
Open AccessUncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury
Traumatic brain injury (TBI) is a highly heterogeneous disease and achieving an accurate diagnosis remains a significant challenge. Biomarkers play a crucial role in minimizing the reliance on invasive techniques like computed tomography, which also have significant economic costs. Human samples were obtained from prospective cohort studies. Mice were subjected to an experimental model of traumatic brain injury. Biomarker levels, gene expression, and blood–brain barrier integrity were analyzed using ELISA, qRT-PCR, and Evans Blue assay; data were statistically evaluated using parametric or non-parametric tests as appropriate. This study focuses on evaluating the role of matricellular protein thrombospondin-1 (TSP-1) and the tight junction proteins occludin and ZO-1 as potential biomarkers of TBI. We showed that lower serum TSP-1 levels correlated with poor patient outcomes at 6 months compared to those patients with a good outcome. Additionally, the disruption of the blood–brain barrier (BBB) and subsequent release of tight junction proteins allowed us to identify occludin as a potential biomarker for prognosis in a cohort of TBI patients and as a diagnosis biomarker in a subgroup of patients with mild TBI, but its discriminative power as a diagnosis biomarker appears modest, as reflected by an AUC of 0.693. On the other hand, ZO-1 exhibited increased levels but limited diagnostic utility. These findings highlight the critical role of TSP-1 in maintaining BBB integrity and regulating the inflammatory response after a TBI, supported by the worsened condition observed in TSP-1-deficient animals. These results demonstrate the potential of TSP-1 and occludin as valuable biomarkers for secondary injury and disease progression in patients with mild to moderate/severe TBI.
- Open Access
- 17 November 2025
- Published by MDPI AG in Preprints.org
Uncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury
Background: Traumatic brain injury (TBI) is a highly heterogeneous disease and achieving an accurate diagnosis remains a significant challenge. Biomarkers play a crucial role in minimizing the reliance on invasive techniques like computed tomography, which also have significant economic costs. Methods: Human samples were obtained from prospective cohort studies. Mice were subjected to an experimental model of traumatic brain injury. Biomarker levels, gene expression, and blood-brain barrier integrity were analyzed using ELISA, qRT-PCR, and Evans Blue assay; data were statistically evaluated using parametric or non-parametric tests as appropriate. Results: This work focuses on evaluating the role of matricellular protein thrombospondin-1 (TSP-1) and the tight junction proteins occludin and ZO-1 as potential biomarkers of TBI. We showed that lower serum TSP-1 levels correlated with poor patient outcome at 6 months compared to those patients with a good outcome. Additionally, the disruption of the blood-brain barrier (BBB) and subsequent release of tight junction proteins allowed us to identify occludin as a potential biomarker for prognosis in a cohort of TBI patients and as a diagnosis biomarker in a subgroup of patients with mild TBI. Conclusions: These findings highlight the critical role of TSP-1 in maintaining the BBB integrity and regulating the inflammatory response after TBI, supported by the worsened condition observed in TSP-1-deficient animals. These results demonstrate the potential of TSP-1 and occludin as valuable biomarkers for secondary injury and disease progression in patients with mild to moderate-severe TBI.
- 17 November 2025
- Published by MDPI AG in Preprints.org
Open AccessUncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury
Background: Traumatic brain injury (TBI) is a highly heterogeneous disease and achieving an accurate diagnosis remains a significant challenge. Biomarkers play a crucial role in minimizing the reliance on invasive techniques like computed tomography, which also have significant economic costs. Methods: Human samples were obtained from prospective cohort studies. Mice were subjected to an experimental model of traumatic brain injury. Biomarker levels, gene expression, and blood-brain barrier integrity were analyzed using ELISA, qRT-PCR, and Evans Blue assay; data were statistically evaluated using parametric or non-parametric tests as appropriate. Results: This work focuses on evaluating the role of matricellular protein thrombospondin-1 (TSP-1) and the tight junction proteins occludin and ZO-1 as potential biomarkers of TBI. We showed that lower serum TSP-1 levels correlated with poor patient outcome at 6 months compared to those patients with a good outcome. Additionally, the disruption of the blood-brain barrier (BBB) and subsequent release of tight junction proteins allowed us to identify occludin as a potential biomarker for prognosis in a cohort of TBI patients and as a diagnosis biomarker in a subgroup of patients with mild TBI. Conclusions: These findings highlight the critical role of TSP-1 in maintaining the BBB integrity and regulating the inflammatory response after TBI, supported by the worsened condition observed in TSP-1-deficient animals. These results demonstrate the potential of TSP-1 and occludin as valuable biomarkers for secondary injury and disease progression in patients with mild to moderate-severe TBI.
- Open Access
- 18 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf424
Ventriculitis: A Retrospective Cohort Study of Clinical Features, Outcomes, and Device Management Practices.
Background: Ventriculitis is a severe central nervous system infection, often secondary to intraventricular device use or neurosurgical procedures, with high morbidity and mortality. Diagnostic criteria remain debated and treatment strategies lack standardization. Methods: We conducted a retrospective cohort study from 2014 to 2022 to describe the clinical characteristics, microbiological profile, treatment strategies, and outcomes of ventriculitis at a tertiary care center. Additionally, we compared outcomes before and after the implementation of an updated intraventricular device management protocol. Results: A total of 403 positive CSF cultures were identified during the study period. Among these, 87 fulfilled clinical and microbiological criteria for ventriculitis. Healthcare-associated cases predominated (73, 83.9%), with neurosurgical interventions (72, 82.8%) and external ventricular drain use (54, 62.1%) as the most prevalent risk factors. The most common pathogens were coagulase-negative Staphylococci (42, 48.3%), particularly Staphylococcus epidermidis (33, 37.9%). Fever (56, 64.4%) and altered consciousness (40, 45.9%) were the most frequent symptoms. Attributable mortality reached 33.3% (29/87), increasing to 39.1% (34/87) within one-year post-episode. The introduction of the updated protocol may have contributed to a reduction in mortality between the study periods [RR 0.45 (0.32–0.78) p=0.003]. Among discharged patients, 67.3% (37/55) experienced neurological sequelae. Predictors of higher mortality included CSF protein ≥1 mg/mL at diagnosis and a Glasgow Coma Scale score ≤8 during the clinical course. Conclusions: Ventriculitis remains a complex and life-threatening condition with considerable diagnostic and management challenges. Our findings suggest that standardized intraventricular device care protocols may contribute to improved outcomes, although further evaluation is needed.
- 18 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf424
Open AccessVentriculitis: A Retrospective Cohort Study of Clinical Features, Outcomes, and Device Management Practices.
Background: Ventriculitis is a severe central nervous system infection, often secondary to intraventricular device use or neurosurgical procedures, with high morbidity and mortality. Diagnostic criteria remain debated and treatment strategies lack standardization. Methods: We conducted a retrospective cohort study from 2014 to 2022 to describe the clinical characteristics, microbiological profile, treatment strategies, and outcomes of ventriculitis at a tertiary care center. Additionally, we compared outcomes before and after the implementation of an updated intraventricular device management protocol. Results: A total of 403 positive CSF cultures were identified during the study period. Among these, 87 fulfilled clinical and microbiological criteria for ventriculitis. Healthcare-associated cases predominated (73, 83.9%), with neurosurgical interventions (72, 82.8%) and external ventricular drain use (54, 62.1%) as the most prevalent risk factors. The most common pathogens were coagulase-negative Staphylococci (42, 48.3%), particularly Staphylococcus epidermidis (33, 37.9%). Fever (56, 64.4%) and altered consciousness (40, 45.9%) were the most frequent symptoms. Attributable mortality reached 33.3% (29/87), increasing to 39.1% (34/87) within one-year post-episode. The introduction of the updated protocol may have contributed to a reduction in mortality between the study periods [RR 0.45 (0.32–0.78) p=0.003]. Among discharged patients, 67.3% (37/55) experienced neurological sequelae. Predictors of higher mortality included CSF protein ≥1 mg/mL at diagnosis and a Glasgow Coma Scale score ≤8 during the clinical course. Conclusions: Ventriculitis remains a complex and life-threatening condition with considerable diagnostic and management challenges. Our findings suggest that standardized intraventricular device care protocols may contribute to improved outcomes, although further evaluation is needed.
- Open Access
Impact of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients: a nationwide study in Spain
Objective: To assess the effect of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients in Spain. Settings: The initial flood of COVID-19 patients overwhelmed an unprepared healthcare system. Different measures were taken to deal with this overburden. The effect of these measures on neurosurgical patients, as well as the effect of COVID-19 itself, has not been thoroughly studied. Participants: This was a multicentre, nationwide, observational retrospective study of patients who underwent any neurosurgical operation from March to July 2020. Interventions: An exploratory factorial analysis was performed to select the most relevant variables of the sample. Primary and secondary outcome measures: Univariate and multivariate analyses were performed to identify independent predictors of mortality and postoperative SARS-CoV-2 infection. Results: Sixteen hospitals registered 1677 operated patients. The overall mortality was 6.4%, and 2.9% (44 patients) suffered a perioperative SARS-CoV-2 infection. Of those infections, 24 were diagnosed postoperatively. Age (OR 1.05), perioperative SARS-CoV-2 infection (OR 4.7), community COVID-19 incidence (cases/10 5 people/week) (OR 1.006), postoperative neurological worsening (OR 5.9), postoperative need for airway support (OR 5.38), ASA grade ≥3 (OR 2.5) and preoperative GCS 3–8 (OR 2.82) were independently associated with mortality. For SARS-CoV-2 postoperative infection, screening swab test 5 people/week) (OR 1.011), preoperative cognitive impairment (OR 2.784), postoperative sepsis (OR 3.807) and an absence of postoperative complications (OR 0.188) were independently associated. Conclusions: Perioperative SARS-CoV-2 infection in neurosurgical patients was associated with an increase in mortality by almost fivefold. Community COVID-19 incidence (cases/10 5 people/week) was a statistically independent predictor of mortality. Trial registration number: CEIM 20/217.
Open AccessImpact of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients: a nationwide study in Spain
Objective: To assess the effect of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients in Spain. Settings: The initial flood of COVID-19 patients overwhelmed an unprepared healthcare system. Different measures were taken to deal with this overburden. The effect of these measures on neurosurgical patients, as well as the effect of COVID-19 itself, has not been thoroughly studied. Participants: This was a multicentre, nationwide, observational retrospective study of patients who underwent any neurosurgical operation from March to July 2020. Interventions: An exploratory factorial analysis was performed to select the most relevant variables of the sample. Primary and secondary outcome measures: Univariate and multivariate analyses were performed to identify independent predictors of mortality and postoperative SARS-CoV-2 infection. Results: Sixteen hospitals registered 1677 operated patients. The overall mortality was 6.4%, and 2.9% (44 patients) suffered a perioperative SARS-CoV-2 infection. Of those infections, 24 were diagnosed postoperatively. Age (OR 1.05), perioperative SARS-CoV-2 infection (OR 4.7), community COVID-19 incidence (cases/10 5 people/week) (OR 1.006), postoperative neurological worsening (OR 5.9), postoperative need for airway support (OR 5.38), ASA grade ≥3 (OR 2.5) and preoperative GCS 3–8 (OR 2.82) were independently associated with mortality. For SARS-CoV-2 postoperative infection, screening swab test 5 people/week) (OR 1.011), preoperative cognitive impairment (OR 2.784), postoperative sepsis (OR 3.807) and an absence of postoperative complications (OR 0.188) were independently associated. Conclusions: Perioperative SARS-CoV-2 infection in neurosurgical patients was associated with an increase in mortality by almost fivefold. Community COVID-19 incidence (cases/10 5 people/week) was a statistically independent predictor of mortality. Trial registration number: CEIM 20/217.
- Open Access
- 25 May 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (6) , 599
Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.
- 25 May 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (6) , 599
Open AccessSerum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.
- Open Access
- 1 June 2019
- Published by Elsevier in Neurología
- Vol. 34 (5) , 318-325
Siringomielia no secundaria a Chiari. Actualización en fisiopatología y manejo
- 1 June 2019
- Published by Elsevier in Neurología
- Vol. 34 (5) , 318-325
Open AccessSiringomielia no secundaria a Chiari. Actualización en fisiopatología y manejo
- Open Access
- 9 May 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (15) , 2764-2779
Early toll‐like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro‐inflammatory phenotype in rodent and human brain ischaemia models
Background and Purpose: Ischaemic stroke is a leading cause of death, disability, and a high unmet medical need. Post‐reperfusion inflammation and an up‐regulation of toll‐like receptor 4 (TLR4), an upstream sensor of innate immunity, are associated with poor outcome in stroke patients. Here, we identified the therapeutic effect of targeting the LPS/TLR4 signal transduction pathway.Experimental Approach: We tested the effect of the TLR4 inhibitor, eritoran (E5564) in different in vitro ischaemia‐related models: human organotypic cortex culture, rat organotypic hippocampal cultures, and primary mixed glia cultures. We explored the therapeutic window of E5564 in the transient middle cerebral artery occlusion model of cerebral ischaemia in mice.Key Results: In vivo, administration of E5564 1 and 4 hr post‐ischaemia reduced the expression of different pro‐inflammatory chemokines and cytokines, infarct volume, blood–brain barrier breakdown, and improved neuromotor function, an important clinically relevant outcome. In the human organotypic cortex culture, E5564 reduced the activation of microglia and ROS production evoked by LPS.Conclusion and Implications: TLR4 signalling has a causal role in the inflammation associated with a poor post‐stroke outcome. Importantly, its inhibition by eritoran (E5564) provides neuroprotection both in vitro and in vivo, including in human tissue, suggesting a promising new therapeutic approach for ischaemic stroke.
- 9 May 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (15) , 2764-2779
Open AccessEarly toll‐like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro‐inflammatory phenotype in rodent and human brain ischaemia models
Background and Purpose: Ischaemic stroke is a leading cause of death, disability, and a high unmet medical need. Post‐reperfusion inflammation and an up‐regulation of toll‐like receptor 4 (TLR4), an upstream sensor of innate immunity, are associated with poor outcome in stroke patients. Here, we identified the therapeutic effect of targeting the LPS/TLR4 signal transduction pathway.Experimental Approach: We tested the effect of the TLR4 inhibitor, eritoran (E5564) in different in vitro ischaemia‐related models: human organotypic cortex culture, rat organotypic hippocampal cultures, and primary mixed glia cultures. We explored the therapeutic window of E5564 in the transient middle cerebral artery occlusion model of cerebral ischaemia in mice.Key Results: In vivo, administration of E5564 1 and 4 hr post‐ischaemia reduced the expression of different pro‐inflammatory chemokines and cytokines, infarct volume, blood–brain barrier breakdown, and improved neuromotor function, an important clinically relevant outcome. In the human organotypic cortex culture, E5564 reduced the activation of microglia and ROS production evoked by LPS.Conclusion and Implications: TLR4 signalling has a causal role in the inflammation associated with a poor post‐stroke outcome. Importantly, its inhibition by eritoran (E5564) provides neuroprotection both in vitro and in vivo, including in human tissue, suggesting a promising new therapeutic approach for ischaemic stroke.
- 3 April 2019
- Published by Wiley in Journal of Pineal Research
- Vol. 67 (1) , e12578
Pharmacological doses of melatonin impede cognitive decline in tau‐related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux
Alterations in autophagy are increasingly being recognized in the pathogenesis of proteinopathies like Alzheimer's disease (AD). This study was conducted to evaluate whether melatonin treatment could provide beneficial effects in an Alzheimer model related to tauopathy by improving the autophagic flux and, thereby, prevent cognitive decline. The injection of AAV‐hTauP301L viral vectors and treatment/injection with okadaic acid were used to achieve mouse and human ex vivo, and in vivo tau‐related models. Melatonin (10 μmol/L) impeded oxidative stress, tau hyperphosphorylation, and cell death by restoring autophagy flux in the ex vivo models. In the in vivo studies, intracerebroventricular injection of AAV‐hTauP301L increased oxidative stress, neuroinflammation, and tau hyperphosphorylation in the hippocampus 7 days after the injection, without inducing cognitive impairment; however, when animals were maintained for 28 days, cognitive decline was apparent. Interestingly, late melatonin treatment (10 mg/kg), starting once the alterations mentioned above were established (from day 7 to day 28), reduced oxidative stress, neuroinflammation, tau hyperphosphorylation, and caspase‐3 activation; these observations correlated with restoration of the autophagy flux and memory improvement. This study highlights the importance of autophagic dysregulation in tauopathy and how administration of pharmacological doses of melatonin, once tauopathy is initiated, can restore the autophagy flux, reduce proteinopathy, and prevent cognitive decline. We therefore propose exogenous melatonin supplementation or the development of melatonin derivatives to improve autophagy flux for the treatment of proteinopathies like AD.
- 3 April 2019
- Published by Wiley in Journal of Pineal Research
- Vol. 67 (1) , e12578
Pharmacological doses of melatonin impede cognitive decline in tau‐related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux
Alterations in autophagy are increasingly being recognized in the pathogenesis of proteinopathies like Alzheimer's disease (AD). This study was conducted to evaluate whether melatonin treatment could provide beneficial effects in an Alzheimer model related to tauopathy by improving the autophagic flux and, thereby, prevent cognitive decline. The injection of AAV‐hTauP301L viral vectors and treatment/injection with okadaic acid were used to achieve mouse and human ex vivo, and in vivo tau‐related models. Melatonin (10 μmol/L) impeded oxidative stress, tau hyperphosphorylation, and cell death by restoring autophagy flux in the ex vivo models. In the in vivo studies, intracerebroventricular injection of AAV‐hTauP301L increased oxidative stress, neuroinflammation, and tau hyperphosphorylation in the hippocampus 7 days after the injection, without inducing cognitive impairment; however, when animals were maintained for 28 days, cognitive decline was apparent. Interestingly, late melatonin treatment (10 mg/kg), starting once the alterations mentioned above were established (from day 7 to day 28), reduced oxidative stress, neuroinflammation, tau hyperphosphorylation, and caspase‐3 activation; these observations correlated with restoration of the autophagy flux and memory improvement. This study highlights the importance of autophagic dysregulation in tauopathy and how administration of pharmacological doses of melatonin, once tauopathy is initiated, can restore the autophagy flux, reduce proteinopathy, and prevent cognitive decline. We therefore propose exogenous melatonin supplementation or the development of melatonin derivatives to improve autophagy flux for the treatment of proteinopathies like AD.
- 23 May 2018
- Published by Singular People Europe S.L. in Neurorecordings
- p. 1
Meningioma microquístico
- 1 May 2018
- Published by Elsevier in Neurocirugia
- Vol. 29 (3) , 116-121
Resultados quirúrgicos de fracturas cervicales traumáticas en pacientes con espondilitis anquilosante
- 1 May 2018
- Published by Elsevier in Neurocirugia
- Vol. 29 (3) , 116-121
Resultados quirúrgicos de fracturas cervicales traumáticas en pacientes con espondilitis anquilosante